Detection of IgM and IgG antibodies in patients with coronavirus disease 2019

Abstract

Objectives This study aimed to determine the IgM and IgG responses against severe acute respiratory syndrome coronavirus (SARS‐CoV)‐2 in coronavirus disease 2019 (COVID‐19) patients with varying illness severities. Methods IgM and IgG antibody levels were assessed via chemiluminescence immunoassay in 338 COVID‐19 patients. Results IgM levels increased during the first week after SARS‐CoV‐2 infection, peaked 2 weeks and then reduced to near‐background levels in most patients. IgG was detectable after 1 week and was maintained at a high level for a long period. The positive rates of IgM and/or IgG antibody detections were not significantly different among the mild, severe and critical disease groups. Severe and critical cases had higher IgM levels than mild cases, whereas the IgG level in critical cases was lower than those in both mild and severe cases. This might be because of the high disease activity and/or a compromised immune response in critical cases. The IgM antibody levels were slightly higher in deceased patients than recovered patients, but IgG levels in these groups did not significantly differ. A longitudinal detection of antibodies revealed that IgM levels decreased rapidly in recovered patients, whereas in deceased cases, either IgM levels remained high or both IgM and IgG were undetectable during the disease course. Conclusion Quantitative detection of IgM and IgG antibodies against SARS‐CoV‐2 quantitatively has potential significance for evaluating the severity and prognosis of COVID‐19.

Cited by papers we hold 7

• A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV · 2022
  Not checked
• Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes · 2021
  Not checked
• A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity · 2021
  No notice
• Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19 · 2021
  No notice
• “COVID Vaccine” is not the excuse to delay adaptation to the “New-Normal” · 2020
  Not checked
• Antibody response to SARS-CoV-2 infection in humans: A systematic review · 2020
  No notice
• Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2 · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.